16TH INTERNATIONAL WORKSHOP on Multiple Endocrine NeoplasiaA Focus on New Concepts and Treatment of Malignant Manifestations

March 27-29, 2019Houston, Texas

The University of TexasMD Anderson Cancer CenterDan L. Duncan Building (CPB)Floor 8, Rooms 1-81155 Pressler StreetHouston, Texas

Register at www.men2019.com

FocusIn keeping with the spirit of the original MEN workshop, MEN2019 will focus on emerging topics in the genesis and therapy of malignant endocrine tumors associated with multiple endocrine neoplasia. The goal of the workshop will be to provide an outline for basic and clinical research focused on these malignant manifestations. The meeting will bring together local and international experts on multiple endocrine neoplasia to focus on these subjects.

A significiant portion of the meeting will be spent in workshops centered on emerging topics and the development of an international roadmap for future research and clinical trials.

The remainder of the meeting will be composed of large group didactic sessions. The University of Texas MD Anderson Cancer Center is a leader in the development of new therapies for cancer. Our goal is to combine the extensive local scientific and clinical talent at MD Anderson along with international experts to allow focus on emerging topics including new directions in immunotherapy, emerging concepts in the use of signaling pathway inhibitors, genetic diagnosis & therapy and new clinical advances that impact management of endocrine tumor syndromes.

A specific outcome of this conference will be a white paper summarizing the goals of this work.

Educational ObjectivesAfter attending the conference, participants should be able to:• Identify and utilize alternative therapies

to the traditional targeted therapy for the treatment of medullary thyroid cancer that may benefit their patients (Knowledge, Competence, Performance);

• Gain an awareness of modern therapy for pancreatic neuroendocrine tumors so that the most efficacious therapy may be delivered (Knowledge, Competence, Performance, Patient Outcomes);

• Utilize options to treat symptoms of excessive hormonal secretion in patients with malignant pheochromocytoma and paraganglioma (Knowledge, Competence, Performance);

• Understand menin function and telomere biology in pancreatic neuroendocrine tumors (Knowledge);

• Appreciate the clinical trials available for patients with parathyroid cancer and enroll them appropriately (Knowledge, Competence, Performance);

• Understand basic, clinical, and translational genetics with regard to TP53 germline predisposition in ACC patients (Knowledge).

Educational Methods• Lecture/Didactic• Poster Session• Interactive Groups/Breakouts

Target AudienceThis conference should be of value to clinicians (including physicians, nurse practitioners, physician assistants and genetic counselors), researchers and trainees (students, residents, and fellows).

EvaluationA conference evaluation link will be included in the final program. This online survey will provide participants with the opportunity to comment on the value of the program content

to their practice decisions, performance improvement activities, or possible impact on patient health status. Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics.

Accreditation/Credit DesignationPhysicians

The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 16.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Certificates and Attendance Verification CertificatesCertificates awarding AMA PRA Category 1 Credit™ or certificates documenting attendance will be emailed when an individual completes the online CME Verification process.

Presentations – WILL BE AVAILABLE

AFTER THE CONFERENCE

All of the PowerPoint presentations will be posted online after the conference. You will receive an invitation email from Study@MD Anderson to create a username and password to log into Study. If you do not receive this instructional email by April 8, 2019, please email ambaring@mdanderson.org.

Deadline for Abstract Submission is Monday, January 7, 2019.

The Planning Committee invites the submission of abstracts. The goal is to provide the audience an opportunity to collaborate and stimulate discussions specifically on emerging topics in the genesis and therapy of malignant endocrine tumors associated with multiple endocrine neoplasia.

Authors may submit abstracts of completed work, work in progress, or work presented elsewhere.

Abstract Submission Instructions:Abstracts will only be accepted electronically and should be uploaded to: MEN2019@mdanderson.org

Six abstracts will be chosen for an oral presentation. The remainder of the selected abstracts will be presented in a poster session.

The deadline for receipt of abstracts is 11:59 PM CST on Monday, January 7. Notification of acceptance for oral and/or poster presentations will be acknowledged by e-mail by Wednesday, January 23, 2019.

Abstract Formatting Instructions:Please indicate in your abstract whether you would like to be considered for an oral presentation, a poster or both. 200 word limit. Limit abstracts to one page, type in 12-point Times New Roman font, single spaced with one-inch margins, and left justified. Organize the abstract into: Background, Methods, Results, and Conclusions. Define all abbreviations. Include the abstract title, full names, and institutional affiliations of all authors, and e-mail address of the corresponding author at the top of the abstract. Underline the name of the presenting author. Abstracts must not contain copyrighted material unless permission has been obtained by the author/publisher.

Conference Planning Committee

Robert Gagel, MD (Chair)ProfessorEndocrine Neoplasia and Hormonal DisordersMD Anderson Cancer Center

Elizabeth Grubbs, MD (Co-Chair)Associate ProfessorSurgical OncologyMD Anderson Cancer Center

Daniel Halperin, MD (Co-Chair)Assistant ProfessorGastrointestinal Medical OncologyMD Anderson Cancer Center

Steven Waguespack, MD (Co-Chair)ProfessorEndocrine Neoplasia and Hormonal DisordersMD Anderson Cancer Center

Allison Baring, CMPCME Conference PlannerCME/Conference ManagementMD Anderson Cancer Center

Naifa Busaidy, MDAssociate ProfessorEndocrine Neoplasia and Hormonal DisordersMD Anderson Cancer Center

Patricia L. Dahia, MD, PhDAssociate ProfessorDepartment of Medicine and Hematology and Medical OncologyUniversity of Texas Health Science Center at San AntonioSan Antonio, Texas

Mimi Hu, MDProfessorEndocrine Neoplasia and Hormonal DisordersMD Anderson Cancer Center

Camilo Jimenez, MDProfessorEndocrine Neoplasia and Hormonal DisordersMD Anderson Cancer Center

Nancy Perrier, MDProfessorSurgical OncologyMD Anderson Cancer Center

International Committee

Albert Beckers, MD, PhDProfessor of EndocrinologyChu Sart TilmanEndocrinologyLiège, Belgium

Jérôme Bertherat, MD, PhDHeadCenter for Rare Adrenal DiseasesCochin HospitalProfessor of EndocrinologyParis Descartes UniversityParis, France

Maria Luisa Brandi, MD, PhDProfessor of Endocrinology University of Florence Medical School Florence, Italy

Friedhelm Raue, MDProfessor of Internal Medicine / EndocrinologyMedical Faculty University of HeidelbergEndocrine PracticeHeidelberg, Germany

Bruce Robinson, MD, MSc, FRACPHonorary ProfessorMedicineNorthern Clinical SchoolKolling Institute of Medical ResearchThe University of Sydney School of MedicineSydney, Australia

Constantine Stratakis, MD, D(Med)ScScientific DirectorNational Institute of Child Health and Human Development National Institutes of HealthBethesda, Maryland

Raj Thakker, MA MD Cantab, FRCP, FRCPath, FmedSci, FRSMay Professor of MedicineUniversity of OxfordOxford, England

Gerlof D. Valk, MD, PhDProfessorEndocrine OncologyUMC UtrechtUtrecht, Netherlands

T U E S D A Y , M A R C H 2 6

5:30 pm Registration and Welcome Reception – Mays West Lobby

A Celebration of the 50th anniversary of screening for Hereditary Medullary Thyroid Cancer

W E D N E S D A Y , M A R C H 2 7

7:00 am Registration and Continental Breakfast

8:00 Welcome and Opening Remarks

PANCREATIC NEUROENDOCRINE TUMORS

8:30 State of the Science in Pancreatic Neuroendocrine Tumors Daniel Halperin, MD

8:50 Emerging Therapies and Epigenetics Kate Lines, PhD

9:10 Menin and Telomeres in Pancreatic Neuroendocrine Tumors Christopher M. Heaphy, PhD

9:30 Observational Studies of Tumor Growth Samira Sadowski, MD

9:50 Perioperative Clinical Trials Matthew HG Katz, MD

10:10 Poster Preview Presentations - 3 at 5 minutes each

10:25 Break/Poster Viewing

11:10 Plenary Session: Common Failures in Rare Diseases Moderator: Steven Sherman, MD

12:15 Lunch (provided)- Working Lunch in Workshop groups

12:30 pm – 2:30 Disease Site Working Groups (choose one) • Medullary Thyroid Cancer • Parathyroid Cancer • Pancreatic Neuroendocrine Tumor (PNET) • Malignant Pheo/PGL

2:30 Break

MEDULLARY THYROID CANCER

2:45 Emerging Therapies In MTC RET Inhibitor LOXO-292

Lori J. Wirth, MD RET Inhibitor BLU-667 Mimi I. Hu, MD Future Trial Development for MTC Vivek Subbiah, MD

3:30 Transcriptional Targeting of OncoGene Addiction in MTC Matthew D. Ringel, MD

3:50 Lessons Learned From TCGA and Other Large Scale Genomics Programs Kenna Shaw, PhD

4:10 Closing Remarks

4:15 pm Adjourn

T H U R S D A Y , M A R C H 2 8

7:00 am Registration and Continental Breakfast

7:30 Breakfast Talk - Hereditary Gastrointestinal Neuroendocrine Tumors (optional, non-CME) Sponsored by Lexicon

8:00 Welcome and Opening Remarks

MALIGNANT PHEOCHROMOCYTOMA AND PARAGANGLIOMA

8:10 State of the Science in Malignant Pheochromocytoma and Paraganglioma Eric Baudin, MD, PhD

8:30 Radiopharmaceuticals, Tyrosine Kinase Inhibitors and Immunotherapy for Patients with Malignant Pheochromocytoma and Paraganglioma Camilo Jimenez, MD

8:50 Pseudohypoxia as a Therapeutic Target: Lessons from Clusters One and Two Patricia L. Dahia, MD, PhD

9:10 Epigenetic Characteristics of Paraganglioma Syndrome Type 4 Mercedes Robledo, PhD

9:30 Enabling Replicative Immortality in Pheochromocytoma and Paraganglioma Anne-Paule Gimenez-Roqueplo, MD, PhD

9:50 Break/Poster Viewing

10:00 Plenary Session: Immune Checkpoint Blockade in Cancer Therapy: New Insights, Opportunities and Prospects for Cures James Allison, PhD

11:00 Poster Preview Presentations - 3 at 5 minutes each

11:15 Break/Poster Viewing

11:45 Lunch (provided)- Working Lunch in Workshop groups

Conference Agenda

12:00 – 2:00 pm Disease Site Working Groups (choose one) • Medullary Thyroid Cancer • Parathyroid Cancer • Pancreatic Neuroendocrine Tumor (PNET) • Malignant Pheo/PGL

2:00 Break/Poster Viewing

PARATHYROID CANCERS

2:15 Genetic Syndromes of PHPT and Parathyroid Cancer Maria-Luisa Brandi, MD

2:35 Genetic and Molecular Alterations in Parathyroid Cancer Andrew Arnold, MD

2:55 CDC73

3:15 The Role of Local Therapies in Parathyroid Cancer: Surgery and Radiotherapy Nancy Perrier, MD

3:35 Targeted Therapies and Trials in Parathyroid Cancer Naifa Busaidy, MD

3:55 Closing Remarks

4:00 pm Adjourn

6:30 pm Dinner at Space Center Houston

F R I D A Y , M A R C H 2 9

7:00 am Registration and Continental Breakfast

8:00 Welcome and Opening Remarks

PITUITARY, ADRENAL CORTEX AND ADRENOCORTICAL TUMORS

8:10 Aggressive Pituitary Tumors: An Update on Pathologic Features and Genomics Gérald Raverot, MD, PhD

8:25 What is New in Familial Isolated Pituitary Adenoma? Albert Beckers, MD, PhD

8:40 X-LAG: An Update Constantine Stratakis, MD, DMSci

8:55 Adrenocortical Tumors: Novel Insights into Pathogenesis of Malignant Adrenocortical Tumors Tobias Else, MD

9:10 Benign Adrenocortical Tumors Jérôme Bertherat, MD, PhD

9:25 VHL as a Paradigm for the Simultaneous Treatment of Multiple Hereditary Tumors Eric Jonasch, MD

9:40 VHL and Pancreatic NETs: An Update Electron Kebebew, MD

10:30 Break/Poster Viewing

10:45 Summary of Working Groups

12:00 pm Adjourn

The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest that could potentially affect the information presented. MD Anderson also requires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity.

Agendas are subject to change because we are always striving to improve the quality of your educational experience. MD Anderson may substitute faculty with comparable expertise on rare occasions necessitated by illness, schedule conflicts, and so forth.

Photographing, audio taping and videotaping are prohibited.

The University of Texas MD Anderson Cancer Center does not endorse the commercial products, equipment, or services presented by program supporters/exhibitors.

Please let us know what specific topics, issues or questions you wish to see addressed or emphasized in this activity. Fax or e-mail CME/Conference Management. All responses will be forwarded to the Program Chairs for consideration.

M D A N D E R S O N F A C U L T Y

James Allison, PhDProfessor and ChairImmunologyChief Scientific Advisor ad interimVivian L. Smith Distinguished ChairImmunologyDirectorParker Institute for Cancer Immunotherapy (PICI)Executive DirectorImmunotherapy PlatformDeputy DirectorDavid H. Koch Center for Applied Research of Genitourinary Cancers

Naifa Busaidy, MDAssociate ProfessorEndocrine Neoplasia and Hormonal Disorders

Daniel Halperin, MDAssistant ProfessorGastrointestinal Medical Oncology

Mimi I. Hu, MDProfessorEndocrine Neoplasia and Hormonal Disorders

Camilo Jimenez, MDProfessorEndocrine Neoplasia and Hormonal Disorders

Eric Jonasch, MDProfessorGenitourinary Medical Oncology

Matthew HG Katz, MDAssociate ProfessorVice Chair - Research Surgical Oncology

Nancy Perrier, MDProfessorSurgical OncologyChiefSection of Surgical EndocrinologyFellowship Program DirectorSurgical EndocrinologyAssociate Medical DirectorMultidisciplinary Endocrine Center

Kenna Shaw, PhDExecutive DirectorInstitute for Personalized Cancer Therapy

Vivek Subbiah, MDAssociate ProfessorInvestigational Cancer Therapeutics

James C. Yao, MDProfessor and ChairGastrointestinal Medical Oncology

G U E S T F A C U L T Y

Andrew Arnold, MDMurray-Heilig Chair in Molecular MedicineProfessor of Medicine and Genetics and Genome SciencesChiefDivision of Endocrinology and MetabolismDirectorCenter for Molecular Oncology andChief Academic OfficerCarole and Ray Neag Comprehensive Cancer CenterDirectorOffice of Physician-Scientist Career DevelopmentCenter for Molecular OncologyUConn HealthFarmington, Connecticut

Eric Baudin, MD, PhDProfessor and Head Neuroendocrinology Gustave Roussy Cancer CampusVillejuif, France

Albert Beckers, MD, PhDProfessor and ChiefDepartment of EndocrinologyCHU de LiègeDomaine Universitaire du Sart-TilmanLiège, Belgium

Jérôme Bertherat, MD, PhDProfessor Hôpital CochinParis Descartes UniversityParis, France

Maria Luisa Brandi, MDProfessorEndocrinologyUniversity of Florence Medical School Florence, Italy

Patricia L. Dahia, MD, PhDAssociate ProfessorDepartment of Medicine and Hematology and Medical OncologyUniversity of Texas Health Science Center at San AntonioSan Antonio, Texas

Tobias Else, MDAssistant ProfessorMichigan Medicine Endocrine OncologyRogel Cancer CenterAnn Arbor, Michigan

Anne-Paule Gimenez-Roqueplo, MD, PhDProfessor GeneticsGeorges Pompidou European HospitalParis, France

Christopher M. Heaphy, PhDAssistant ProfessorPathology and OncologyThe Johns Hopkins University School of MedicineBaltimore, Maryland

Electron Kebebew, MDProfessor ChiefDivision of General SurgeryHarry A. Oberhelman Jr. and Mark L. Welton ProfessorProgram Leader, Endocrine Oncology ProgramStanford Cancer CenterStanford, California

Kate Lines, PhDPostdoctoral ResearcherUniversity of Oxford Churchill HospitalOxford, United Kingdom

Gérald Raverot, MD, PhDProfessor of Universities – Hospital Practitioner Department of Endocrinology and DiabetologyCHU Lyon HCL - GH East Hospital Louis PradelLyon, France

Matthew D. Ringel, MDRalph W. Kurtz Chair and Professor of MedicineDirectorDivision of Endocrinology, Diabetes, and MetabolismCo-Director, Thyroid Cancer UnitThe James- The Ohio State University Comprehensive Cancer CenterColumbus, Ohio

Mercedes Robledo, PhDHereditary Endocrine Cancer Group, Group LeaderHuman Cancer Genetics ProgramSpanish National Cancer Research Center (CNIO)Madrid, Spain

Samira Sadowski, MDEndocrine SurgeonUniversity Hospitals of GenevaGeneva, Switzerland

Constantine Stratakis, MD, DMSciScientific DirectorNational Institute of Child Health and Human Development National Institutes of HealthBethesda, Maryland

Lori J. Wirth, MDMedical DirectorCenter for Head and Neck CancersMassachusetts General Hospital Cancer CenterBoston, Massachusetts

Registration InformationEarly registration and a Welcome Reception begin at 5:30 pm on Tuesday, March 26. On-site registration will begin at 7:00 am on Wednesday, March 27 and the Welcome and Introductions will begin at 8:00 am. Advanced registration is encouraged as space and materials are limited.

The deadline for advanced registration is Friday, February 15, 2019.

There are three ways to register:1. Online at www.mdanderson.org/conferences2. Fax to: 713-794-17243. Mail to: CME/Conference Management

Unit 1781 The University of Texas MD Anderson Cancer Center P.O. Box 301407 Houston, TX 77230-1407

We accept the following forms of payment:• Check (payable through U.S. banks only)• Money Order• Credit Cards (MasterCard, VISA, and

American Express)• Cash (on-site registration only)

A receipt and confirmation letter will be sent to you within ten working days of receipt of your fee. The conference registration fee includes tuition, final conference agenda, continental breakfasts, breaks, lunch and a welcome reception. Please refer to the registration form for specific information regarding fees.

Refund/Cancellation PolicyThe registration fee, minus a $50 administrative handling fee, is refundable

if a written request is received on or before February 15, 2019. No refunds will be granted after that date. The request for a registration refund must include the tax identification number of the company or institution if registration was paid by a company or institution check.

CME/Conference Management reserves the right to cancel activities prior to the scheduled date, if low enrollment or other circumstances make it necessary. Each registrant will be notified by mail, e-mail, or the contact numbers as given on the registration form. In case of activity cancellation, liability of the CME/Conference Management is limited to the registration fee. CME/Conference Management will refund the full registration fee.

CME/Conference Management reserves the right to limit the number of participants in a program and is not responsible for any expenses incurred by an individual whose registration is not confirmed and for whom space is not available.

For additional information, please contact CME/Conference Management at 713-792-2223 or toll free at 866-849-5866.

Special AssistanceContact CME/Conference Management at 713-792-2223 or toll-free at 866-849-5866 if you have any special dietary or ADA accommodation needs.

Accommodations• A block of rooms has been reserved for

conference attendees at the Wyndham Houston – Medical Center located at 6800 South Main Street, Houston, Texas 77030.

• Early hotel reservation is suggested and the room block cutoff date is: Tuesday, March 5, 2019.

• The hotel phone number is 713-528-7744• When you make reservations, be sure

to mention the group name: Multiple Endocrine Neoplasia 2019 room block to be assured of receiving the special meeting rate of $165 for a single or double guest room. Please add 17% Texas state and local taxes.

Ground Transportation(prices are subject to change and variable depending on location of conference)

• Houston is served by two airports, George Bush Intercontinental (IAH) and William P. Hobby (HOU).

• Taxicabs are available at an estimated cost for $50-60, to or from William P. Hobby Airport or George Bush Intercontinental Airport.

• Super Shuttle operates a shuttle bus between George Bush Intercontinental Airport and the Wyndham Houston Medical Center for $27 one-way and $54 round-trip. For more information, call 713-523-8888 or toll-free at 800-258-3826 or online at www.supershuttle.com.

• Super Shuttle operates a shuttle bus between William P. Hobby Airport and the Wyndham Houston Medical Center for $24 one-way and $48 round-trip. For more information, call 713-523-8888 or toll-free at 800-258-3826 or online at www.supershuttle.com.

We sincerely hope you can join us for dinner at Space Center Houston on Thursday, March 28.

Space Center Houston is the Official Visitor Center of NASA Johnson Space Center, the home of astronaut training, International Mission Control and human space exploration.

Dinner will be held in the Astronaut Gallery beginning at 6:30 pm- You will be able to see the ejection suit that astronaut John Young wore on the first shuttle flight in 1981 along with the T-38 flight suit worn by our second female astronaut and fallen hero, Judy Resnik. You’ll also have an opportunity to see a Saturn V rocket; the tallest, heaviest and most powerful rocket ever brought to operational status and responsible for launching astronauts to the moon. You won’t want to miss this unique experience!

THIS IS NOT A SELF-MAILER - Address to: MEN 2019: 16th International Workshop on Multiple Endocrine Neoplasia-

A Focus on New Concepts and Treatment of Malignant ManifestationsCME/Conference Management – Unit 1781

The University of Texas MD Anderson Cancer Center PO Box 301407, Houston, TX 77230-1407

or fax to 713-794-1724 Make check or money order payable to:

The University of Texas MD Anderson Cancer Center

Registration FeesPostmarked before February 15 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $600Postmarked after February 15 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .$700

Students/Fellows/Residents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $200

MD Anderson Faculty/Staff . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $200

MD Anderson Trainees . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $50

Will you be attending the Tuesday evening reception at MD Anderson? Yes No

Space Center Houston Dinner Ticket (evening of March 28, 2019): (Roundtrip transportation included) ________ x $85/person

Which working group would you like to attend? (Choose One) Final working group composition and number to be confirmed pending registration interest. Medullary Thyroid CancerPNETParathyroid CancerMalignant Pheochromocytoma/Paraganglioma

CONFERENCE REGISTRATION - 176700/30/120473/41MEN 2019: 16th International Workshop on Multiple Endocrine Neoplasia- A Focus on New Concepts and Treatment of Malignant Manifestations — March 27-29, 2019

Last Name First MI Highest Degree

Department (include unit no.) Specialty

Institution

MD Anderson Employee ID No. (required for all MDACC employees): Physician Yes No

Street

City State/Foreign Country/Zip or Mail Code

Daytime Phone (with area code) Cell Phone (with area code) Fax (with area code)

E-mail Address (please print)

Emergency Contact Phone (with area code)

Credit Card Holder Name (First/Last) Charge the following: VISA MC AMEX

Credit Card Number Expiration Date

Security Code/CVV/CSV Credit Card Holder Billing Address & ZIP Code

MD Anderson Interdepartmental Transfer (IDT) No .: *Fund Group 90 will not be accepted

Business Unit Department Fund Group* Fund Fund Type

Authorized Signature REQUIRED for CREDIT CARD or IDT IDT Approver Name (First/Last) please print